Data from multiple sources - Curated by Toby Galbraith - Last updated 04 January 2017

Latest news articles

Added 23 hours ago Drug news

Data review of Phase III study of Macrilen (macimorelin) for the evaluation of growth hormone deficiency in adults. -Aeterna Zentaris Inc.

Aeterna Zentaris Inc. announced that, following a comprehensive review of data obtained from the confirmatory Phase III clinical trial of...

Added 9 days ago Drug news

FDA issues warning relating to ReShape and Obera balloon systems that are associated with overinflation and acute pancreatitis.-ReShape Medical and Apollo Endo-Surgery.

The FDA has recently received multiple reports for two different types of adverse events associated with fluid-filled intragastric balloons used...

Added 12 days ago Drug news

Phase III results from VBLOC DM2 Study of vBloc neurometabolic therapy in obese patients with type 2 diabetes published- EnteroMedics

EnteroMedics announced the publication of three-year data from the Company's VBLOC DM2 Study of vBloc Neurometabolic Therapy in obese patients...

View all news articles


Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.


Epidemiology, pathophysiology, diagnosis/treatment guidelines, recent publication summaries and more

Visit Hypogonadism

Lysosomal Acid Lipase Deficiency (LAL-D)

Could you correctly diagnose and treat lysosomal acid lipase deficiency?

Visit Lysosomal Acid Lipase Deficiency (LAL-D)

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more

Visit Type 2 Diabetes



Adalimumab for the treatment of adults with psoriasis

The severity of a person's psoriasis before and during treatment should be assessed by considering the redness, thickness and scaliness of the plaques, the area of the body involved, and how the condition...

Added 6 days ago

British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009

Psoriasis is a common, chronic inflammatory skin disease which typically follows a relapsing and remitting course, and is associated with joint disease in approximately 25% of patients.

Added 6 days ago

Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasis

To provide the dermatologist a guide focuses specifically on the diagnosis and management of the diseases most often found in patients with psoriasis.

Added 6 days ago

View all guidelines

Journal articles

Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis.

Interleukin-17A (IL-17A) is elaborated by the T helper 17 (T(H)17) subset of T(H) cells and exhibits potent proinflammatory properties in animal models of autoimmunity, including collagen-induced arthritis, experimental ...

Added 2 days ago

Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis.

The articles by Papp and colleagues and Leonardi and colleagues (both in the March 29 issue) attest to the growing interest in the therapeutic potential of agents such as ixekizumab and...

Added 2 days ago

Treatment with the interleukin-17a-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: Results of an open-label, parallel-group, randomised single-center study

Our objective was to evaluate the efficacy of influenza and meningococcal vaccinations in healthy subjects exposed to the anti-interleukin-17A (IL-17A) monoclonal antibody (MAb) secukinumab.

Added 2 days ago

View all journal articles

Clinical trials

A Randomized, Double-blind, Placebo Controlled, Multicenter Regimen Finding Study of Subcutaneously Administered AIN457, Assessing Psoriasis Area and Severity Index (PASI) Response in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

The purpose of the study is to determine whether, in patients with moderate to severe plaque-type psoriasis, AIN457 administered subcutaneously reduces the severity of psoriasis symptoms and the extent...

Added 1 day ago

A Dose-Ranging And Efficacy Study of LY2439821 (An Anti-IL-17 Antibody) In Patients With Moderate-To-Severe Psoriasis

The safety of ixekizumab (LY2439821) and any side effects that might be associated with it....

Added 1 day ago

A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period

This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.

Added 5 days ago

View all clinical trials

Blog Posts

Joyce Lee

Healthcare Provider: Think Like a Designer!

Posted 1 year ago

Joyce Lee puts forward the case for healthcare providers using goal-directed design. Should we treat patients in order to facilitate their personal treatment goals rather than aiming to simply reduce their symptoms? Do statistical and scientific methodologies neglect the psychosocial emotional management of patients?

Partha Kar

Changing paradigms for Diabetes care in Britain's NHS

Posted 2 years ago

Diabetes care is a hot topic in medicine since it touches so many primary care settings; from maternity to foot care, Diabetes has multiple other pathologies. When does Diabetes care necessitate the role of a specialist? How can diabetologists ensure they work innovatively and make the patient's healthcare journey as seamless as possible? Dr. Partha Kar dives in, asking how healthcare professionals can make positive change to patients with Diabetes in Britain's NHS.

Partha Kar

Type 1 diabetes: The ignored populace? (part 1)

Posted 1 year ago

Is it possible to have choice in a system where healthcare is "free"? Does it lend itself to the pathology of type 1 diabetes? A pathology subsumed within the bigger world of type 2 diabetes, a combination of media driven ignorance, apathy, lack of leadership and commissioning issues have reduced this condition to being part of "diabetes" as a whole.

In this 2 part blog, we try to explore the challenges and possible solutions to how we could offer this group of patients better care than what seems to be the norm nowadays.